Atria Investments LLC Halozyme Therapeutics, Inc. Transaction History
Atria Investments LLC
- $7.33 Billion
- Q1 2025
A detailed history of Atria Investments LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Atria Investments LLC holds 11,527 shares of HALO stock, worth $628,682. This represents 0.01% of its overall portfolio holdings.
Number of Shares
11,527
Previous 10,078
14.38%
Holding current value
$628,682
Previous $481,000
52.81%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
595Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$961 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$700 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$330 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$212 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$200 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.6B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...